Article

Sirion, AVR promote retinal and meibomian gland health

Sirion Therapeutics Inc. has entered into an agreement with Advanced Vision Research Inc. (AVR) of Woburn, MA, to co-promote AVR's new oral retinal nutritional supplement (MacuTrition) and its product for meibomian gland therapy (NutriDox Convenience Kit).

Tampa, FL

-Sirion Therapeutics Inc. has entered into an agreement with Advanced Vision Research Inc. (AVR) of Woburn, MA, to co-promote AVR’s new oral retinal nutritional supplement (MacuTrition) and its product for meibomian gland therapy (NutriDox Convenience Kit). Sirion’s sales force will promote actively the two products as well as provide sampling for the company’s line of topical drops to treat dry eye.

The oral nutritional supplement aims to address the factors that threaten long-term eye and general health. These factors include oxidation, inflammation, and neovascularization, which also are risks in patients with macular degeneration and diabetic retinopathy. The supplement includes a combination of antioxidants, anti-inflammatories, and anti-angiogenics that include fish oil omega-3 fatty acids, vitamin D, green tea extract, and vitamin E.

Meibomitis is a precursor to meibomian gland dysfunction. The condition is characterized by excess bacteria in the eye lid margins, increased vascularization of the lids, and loss of normal meibomian gland anatomy and function, which contribute to decreased quality and quantity of meibomian lips, tear-film lipid layer deficiency, and increased tear-film evaporation. The convenience kit includes doxycycline (75 mg), an omega-3 supplement with optimized flaxseed/fish oil blend (TheraTears Nutrition), and a portable warm compress system for symptom relief (iHeat).

“Sirion and [AVR] share a joint focus on healthy eyes for patients through clinical research and innovation in ocular disease,” said Jeffrey P. Gilbard, MD, founder, chief executive officer, and chief scientific officer of AVR, in a prepared statement. Dr. Gilbard also is a clinical assistant professor of ophthalmology at Harvard Medical School and director of the Dry Eye and Ocular Surface Disease Clinic at the New England Eye Center, Boston.

“Sirion’s resources and specialized sales force will be instrumental in helping AVR promote retinal and meibomian gland health and provide relief for dry-eye patients,” he said.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.